HAVCR2 and melanoma: With regard to these results, studies in murine models of melanoma, colorectal cancer and AML have analyzed checkpoint co-blockades, and demonstrated greater T cell responses following TIM-3 and PD-1 co-blockades compared to PD-1 inhibition alone [36,47,48].